Skip to content

The Beauty Health Company SKIN Options canceled (in dollars per share)

Options canceled (in dollars per share) at other companies

SANUWAVE Health, Inc. logo
SANUWAVE Health, Inc.SNWV
$21.82

Other financials

Income statement

See full
Revenue$64.9M-6.7%
Gross profit$44.4M-8.5%
Operating income-$1.8M+85.0%
Net income-$6.6M+34.3%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$204.4M-45.2%
Total debt$125.9M+756%
Total equity$55.2M+19.9%
Total assets$473.2M-29.8%

Cash flow

See full
Operating cash flow-$5.6M-285%
CapEx$224.0K+398%
Free cash flow-$5.8M-296%

Valuation

See full
Market cap$89.75M-61.5%
Enterprise value$11.24M-96.2%
P/S0.3×-0.4×

Profitability

See full
Gross margin64.9%+8.3pp
Operating margin-3.6%-1.6pp
Net margin-2%-0.9pp
FCF margin9.6%

Returns & leverage

See full
Return on equity-12%-5.4pp
Debt / equity2.3×+2.0×
Current ratio1.8×-5.7×

Where this comes from

Reported directly by The Beauty Health Company in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.

The official record: The Beauty Health Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Beauty Health Company's options canceled (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Beauty Health Company's options canceled (in dollars per share)?
The Beauty Health Company (SKIN) reported options canceled (in dollars per share) of $0.00 in Q1 2026.
How has The Beauty Health Company's options canceled (in dollars per share) changed year-over-year?
The Beauty Health Company's options canceled (in dollars per share) decreased by 100.0% year-over-year, from $14.90 to $0.00.
What does options canceled (in dollars per share) mean?
Indicates the per-share value associated with stock options that were canceled or terminated before vesting. It provides transparency into the dilution impact and the accounting treatment of equity incentives.